lu codes
Source: ODB Formulary/CDI, edition 43 (effective 2026-04-28). Checked weekly for updates. Unofficial search tool.
/
showing 10 of 12 drugs (26 codes)
ACARBOSE Glucobay, Mar-Acarbose
In patients who cannot tolerate or have failed treatment with other oral hypoglycemic agents or in whom other oral hypoglycemic agents are contraindicated;
Indefinite
In patients who require combination therapy with more than one oral hypoglycemic agent to control their serum glucose concentrations.
Indefinite
anti-diabetic agents oral anti-diabetic agents
BUDESONIDE Pulmicort Nebuamp, Teva-Budesonide, Taro-Budesonide
Children aged 6 years or less;
Indefinite
Patients who have a tracheostomy;
Indefinite
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Indefinite
Patients with severe mental or physical disabilities;
Indefinite
Patients who have previously used nebulizer therapy within the last 12 month period.
Indefinite
corticosteroids
TESTOSTERONE, TESTOSTERONE CYPIONATE, TESTOSTERONE ENANTHATE, TESTOSTERONE UNDECANOATE Androgel, Taro-Testosterone Gel, Testim, Depo-Testosterone, Taro-Testosterone Cypionate Injection, Delatestryl +4 more
For male patients with confirmed low morning serum testosterone levels associated with documented, symptomatic hypothalamic, pituitary or testicular disease, or in HIV-infected patients.
1 year
Note: Older males with nonspecific symptoms of fatigue, malaise, depression who have a low normal random testosterone level do not satisfy these criteria.
androgens
CONJUGATED ESTROGENS Premarin
For short-term use in women who are experiencing symptoms of menopause.
1 year
Note: Recent evidence has demonstrated that use of hormone replacement therapy (HRT) increases the rate of coronary events, breast cancer, dementia, stroke, venous thromboembolism and referrals for abnormal vaginal bleeding. These risks should be discussed with patients and reviewed periodically.
estrogens
DIENOGEST Visanne, Aspen-Dienogest, Jamp Dienogest, M-Dienogest, Mar-Dienogest
For the management of pelvic pain associated with endometriosis in patients for whom one or more less costly options are either ineffective or cannot be used.
1 year
Note: For example for patients who are refractory to 6 months of continuous combined oral contraceptives and/or medroxyprogesterone therapy OR have contraindications to these therapies.
progestogens and oral contraceptives
TRIAMCINOLONE HEXACETONIDE Trispan
For intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases including:
Indefinite
- Rheumatoid arthritis
- Juvenile Idiopathic Arthritis (JIA)*
- Osteoarthritis and post-traumatic arthritis
- Synovitis, tendinitis, bursitis and epicondylitis
*Note: triamcinolone hexacetonide injectable suspension may also be used as an intra-articular injection in children aged 3-12 years with Juvenile Idiopathic Arthritis.
corticosteroids
INDACATEROL ACETATE & MOMETASONE FUROATE Atectura Breezhaler
For once-daily maintenance treatment of asthma in patients aged 12 years and older with reversible obstructive airways disease.
Indefinite
corticosteroids
INDACATEROL ACETATE & GLYCOPYRRONIUM BROMIDE & MOMETASONE FUROATE Enerzair Breezhaler
For the treatment of asthma in adult patients inadequately controlled with a maintenance combination of a long-acting beta-2 agonist (LABA) and a medium or high dose of an inhaled corticosteroid (ICS), who experienced one or more asthma exacerbations in the previous 12 months.
Indefinite
corticosteroids
TERIPARATIDE Osnuvo, Teva-Teriparatide Injection, Apo-Teriparatide Injection, Forteo
For the treatment of osteoporosis in patients at a high risk of fragility fractures who meet ALL the following criteria:
2 years
- 65 years of age or older; AND
- Has a documented bone mineral density [BMD] T-score of less than or equal to -3; AND
- Has a history of prior fragility fracture(s); AND
- Has used an anti-resorptive agent for osteoporosis which resulted in osteonecrosis of the jaw and/or an atypical femur fracture.
Note: The maximum lifetime exposure to teriparatide for an individual patient is 24 months
For the treatment of osteoporosis in patients at a high risk of fragility fractures who meet ALL the following criteria:
2 years
- 65 years of age or older; AND
- Has a documented bone mineral density [BMD] T-score of less than or equal to -3; AND
- Has a history of prior fragility fracture(s); AND
- Has used an anti-resorptive agent for osteoporosis which resulted in osteonecrosis of the jaw and/or an atypical femur fracture.
Note: The maximum lifetime exposure to teriparatide for an individual patient is 24 months
parathyroid agents
INSULIN GLARGINE Lantus-(Vial)
Patient requires insulin therapy and is unable to use the insulin pen.
1 year
anti-diabetic agents insulins (long acting)
No matching LU codes found.